Literature DB >> 10903648

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

J Danesh1, P Whincup, M Walker, L Lennon, A Thomson, P Appleby, J R Gallimore, M B Pepys.   

Abstract

OBJECTIVE: To assess associations between baseline values of four different circulating markers of inflammation and future risk of coronary heart disease, potential triggers of systemic inflammation (such as persistent infection), and other markers of inflammation.
DESIGN: Nested case-control comparisons in a prospective, population based cohort.
SETTING: General practices in 18 towns in Britain. PARTICIPANTS: 506 men who died from coronary heart disease or had a non-fatal myocardial infarction and 1025 men who remained free of such disease until 1996 selected from 5661 men aged 40-59 years who provided blood samples in 1978-1980. MAIN OUTCOME MEASURES: Plasma concentrations of C reactive protein, serum amyloid A protein, and serum albumin and leucocyte count. Information on fatal and non-fatal coronary heart disease was obtained from medical records and death certificates.
RESULTS: Compared with men in the bottom third of baseline measurements of C reactive protein, men in the top third had an odds ratio for coronary heart disease of 2.13 (95% confidence interval 1.38 to 3.28) after age, town, smoking, vascular risk factors, and indicators of socioeconomic status were adjusted for. Similar adjusted odds ratios were 1.65 (1.07 to 2.55) for serum amyloid A protein; 1.12 (0.71 to 1.77) for leucocyte count; and 0.67 (0.43 to 1.04) for albumin. No strong associations were observed of these factors with Helicobacter pylori seropositivity, Chlamydia pneumoniae IgG titres, or plasma total homocysteine concentrations. Baseline values of the acute phase reactants were significantly associated with one another (P<0.0001), although the association between low serum albumin concentration and leucocyte count was weaker (P=0.08).
CONCLUSION: In the context of results from other relevant studies these findings suggest that some inflammatory processes, unrelated to the chronic infections studied here, are likely to be involved in coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903648      PMCID: PMC27435          DOI: 10.1136/bmj.321.7255.199

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  32 in total

1.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

2.  Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes.

Authors:  A Phillips; A G Shaper; P H Whincup
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

3.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

Authors:  R P Tracy; R N Lemaitre; B M Psaty; D G Ives; R W Evans; M Cushman; E N Meilahn; L H Kuller
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

Review 4.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

5.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F M Sacks; L A Moye; S Goldman; G C Flaker; E Braunwald
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

6.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

7.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.

Authors:  J Cermak; N S Key; R R Bach; J Balla; H S Jacob; G M Vercellotti
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

8.  Rapid automated enzyme immunoassay of serum amyloid A.

Authors:  J Wilkins; J R Gallimore; G A Tennent; P N Hawkins; P C Limburg; M H van Rijswijk; E G Moore; M B Pepys
Journal:  Clin Chem       Date:  1994-07       Impact factor: 8.327

9.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial.

Authors:  L H Kuller; R P Tracy; J Shaten; E N Meilahn
Journal:  Am J Epidemiol       Date:  1996-09-15       Impact factor: 4.897

10.  Leukocyte count and risk of major coronary heart disease events.

Authors:  A N Phillips; J D Neaton; D G Cook; R H Grimm; A G Shaper
Journal:  Am J Epidemiol       Date:  1992-07-01       Impact factor: 4.897

View more
  338 in total

1.  Coronary artery disease--from bench to bedside.

Authors:  R Kharbanda; P Vallance
Journal:  J R Soc Med       Date:  2001-02       Impact factor: 5.344

2.  The renaissance of C reactive protein.

Authors:  M B Pepys; A Berger
Journal:  BMJ       Date:  2001-01-06

3.  Heart disease and the inflammatory response.

Authors:  W Koenig
Journal:  BMJ       Date:  2000-07-22

Review 4.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 5.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 6.  Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review.

Authors:  R Padwal; S E Straus; F A McAlister
Journal:  BMJ       Date:  2001-04-21

Review 7.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

8.  Aspirin use and risk of type 2 diabetes in apparently healthy men.

Authors:  Yasuaki Hayashino; Charles H Hennekens; Tobias Kurth
Journal:  Am J Med       Date:  2009-02-21       Impact factor: 4.965

Review 9.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

10.  Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Authors:  H S Gurm; D L Bhatt; A M Lincoff; J E Tcheng; D J Kereiakes; N S Kleiman; G Jia; E J Topol
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.